All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Scientists from the Cleveland Clinic have reported that the enzyme proprotein convertase subtilisin/kexin-6 (PCSK6) plays a role in blood pressure. Another member of the PCSK family, PCSK9, is the target of two recently approved cholesterol drugs, Praluent (alirocumab, Regeneron Pharmaceuticals Inc./Sanofi SA) and Repatha (evolocumab, Amgen Inc.).